Clinical trial
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly…
NCT00317811 · Oncotherapeutics, Industry · Completed
Key facts
| NCT number | NCT00317811 |
|---|---|
| Title | Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma |
| Official title | A Phase II Trial of Bortezomib + Ascorbic Acid + Melphalan (BAM) Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma |
| Lead sponsor | Oncotherapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Dietary Supplement, Drug |
| Interventions | ascorbic acid, bortezomib, melphalan |
| Enrollment | 35 |
| Start date | Nov 1, 2005 |
| Primary completion | Feb 1, 2009 |
| First posted | Apr 25, 2006 |
| Last update posted | Nov 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: